Building Competitive Advantage with Sustainable Products – A Case Study Perspective of Stakeholders

This is the author accepted manuscript. The final version is available from Elsevier via the DOI in this recordSustainability has gained momentum in literature as government and non-governmental policymakers to fight climate change. Sustainability principles can be good for business and the economy, but businesses have been slow to replace non-sustainable products with sustainable ones. We argue that this is because businesses have a harder time seeing how to build a stronger competitive advantage with sustainable products than they have with the products they already offer. This study thus addresses the question of how sustainable innovators can build competitive advantage around sustainable products. Stakeholder theory advises business owners to build products around the interests of all stakeholders. This paper thus uses a grounded theory approach based on a series of interviews with fifteen key business stakeholders: entrepreneurs, investors, customers, and academics/NGO representatives. There are four major and interconnected findings, viz: (1) investors are the most doubtful concerning sustainable innovations, while customers are receptive and keen to be involved; (2) sustainable entrepreneurs are subsequently advised to make sure that the underlying business case of their firm is well developed as much as the product; (3) the overall barrier hindering the success of some sustainable innovations is not their cost, but the human nature to put off change until problems become critical; and (4) at the moment, investing in sustainable innovations is more attractive in regions with positive sustainability regulations such as California and some European countries.Rochester Institute of Technology, Golisano Institute for Sustainability and Saunders College of Busines

Impact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study

OBJECTIVES: Paediatric cancer is a leading cause of death for children. Children in low-income and middle-income countries (LMICs) were four times more likely to die than children in high-income countries (HICs). This study aimed to test the hypothesis that the COVID-19 pandemic had affected the delivery of healthcare services worldwide, and exacerbated the disparity in paediatric cancer outcomes between LMICs and HICs. DESIGN: A multicentre, international, collaborative cohort study. SETTING: 91 hospitals and cancer centres in 39 countries providing cancer treatment to paediatric patients between March and December 2020. PARTICIPANTS: Patients were included if they were under the age of 18 years, and newly diagnosed with or undergoing active cancer treatment for Acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, Wilms' tumour, sarcoma, retinoblastoma, gliomas, medulloblastomas or neuroblastomas, in keeping with the WHO Global Initiative for Childhood Cancer. MAIN OUTCOME MEASURE: All-cause mortality at 30 days and 90 days. RESULTS: 1660 patients were recruited. 219 children had changes to their treatment due to the pandemic. Patients in LMICs were primarily affected (n=182/219, 83.1%). Relative to patients with paediatric cancer in HICs, patients with paediatric cancer in LMICs had 12.1 (95% CI 2.93 to 50.3) and 7.9 (95% CI 3.2 to 19.7) times the odds of death at 30 days and 90 days, respectively, after presentation during the COVID-19 pandemic (p<0.001). After adjusting for confounders, patients with paediatric cancer in LMICs had 15.6 (95% CI 3.7 to 65.8) times the odds of death at 30 days (p<0.001). CONCLUSIONS: The COVID-19 pandemic has affected paediatric oncology service provision. It has disproportionately affected patients in LMICs, highlighting and compounding existing disparities in healthcare systems globally that need addressing urgently. However, many patients with paediatric cancer continued to receive their normal standard of care. This speaks to the adaptability and resilience of healthcare systems and healthcare workers globally

Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic

Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality